Biognosys Enters Collaboration with Leading Life Science Company to Advance Next-generation Proteomics
14.9.2021 09:00:00 EEST | Business Wire | Press release
Biognosys, an innovator and leader in next-generation proteomics technology and solutions for life sciences research, announced today that they have entered a collaboration with Evotec, a life science company that discovers, develops, and provides highly effective therapeutics for patients, to advance the adoption of next-generation proteomics in drug discovery and clinical research.
Evotec has been a long-term user of Biognosys’ software and kits within its research. The two companies are now working closely together to integrate Biognosys’ next-generation proteomics data analysis platform in drug discovery and clinical proteomics.
Under the extended partnership, Evotec will continue to utilize Spectronaut, Biognosys’ flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics, in its research. The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multidimensional insights into protein expression, function, and structure across all major biological species and sample types.
Additionally, Evotec is implementing Biognosys’ unique workflow for mass spectrometry facility management. This workflow combines Biognosys’ proprietary QuiC software with its patented indexed Retention Time (iRT) technology and iRT Kit to generate near real-time readouts from mass spectrometry instrument raw files for quality control.
The collaboration uniquely combines Evotec’s partnered drug discovery and development business model and focus on data-driven precision medicine, and Biognosys’ expertise and know-how in applying next-generation proteomics to transforming drug discovery and development.
Kristina Beeler, PhD, CBO of Biognosys, comments: “We are excited to deploy the power of proteomics to address some of the key challenges of drug development and work closely with Evotec to de-risk therapeutic assets early on.”
Christoph Schaab, PhD, SVP Head of Proteomics & Metabolomics at Evotec, comments: “Discovery proteomics is increasing its importance to derive functional insights in the early stages of the drug development pipeline. We are thrilled to integrate Biognosys’ proteomics data analysis expertise into Evotec’s pre-clinical and clinical development solutions for the benefit of our biopharma partners.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
About Evotec
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the worldleading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,900 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005750/en/
Contact information
Media Contact Biognosys
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alpaca Expands into Europe with WealthKernel Acquisition and Launch of European Equities Trading21.4.2026 11:49:00 EEST | Press release
Alpaca, a global leader in brokerage infrastructure APIs, today announced the completion of its acquisition of European fintech WealthKernel, marking its expansion into Europe. The company also announced the initial rollout of its API-first equities trading services in Europe, enabling cross-border investing through a single integration. WealthKernel will now operate as Alpaca Europe. The acquisition gives Alpaca licensed brokerage and custody infrastructure in the UK and EU, supporting its ability to deliver investment services and expand its wealth management capabilities across the region. Built on WealthKernel’s regulatory and operational foundation, Alpaca Europe includes UK and EU licenses and local brokerage and custody infrastructure supporting products such as ISAs and SIPPs. Combined with Alpaca’s US-headquartered, licensed and regulated full-stack brokerage infrastructure, it creates a unified infrastructure layer for fintechs and financial institutions building investment p
Alpaca Expands into Europe with WealthKernel Acquisition and Launch of European Equities Trading21.4.2026 11:49:00 EEST | Press release
Alpaca, a global leader in brokerage infrastructure APIs, today announced the completion of its acquisition of European fintech WealthKernel, marking its expansion into Europe. The company also announced the initial rollout of its API-first equities trading services in Europe, enabling cross-border investing through a single integration. WealthKernel will now operate as Alpaca Europe. The acquisition gives Alpaca licensed brokerage and custody infrastructure in the UK and EU, supporting its ability to deliver investment services and expand its wealth management capabilities across the region. Built on WealthKernel’s regulatory and operational foundation, Alpaca Europe includes UK and EU licenses and local brokerage and custody infrastructure supporting products such as ISAs and SIPPs. Combined with Alpaca’s US-headquartered, licensed and regulated full-stack brokerage infrastructure, it creates a unified infrastructure layer for fintechs and financial institutions building investment p
Comwrap Reply Recognized With the Adobe CXO Emerging Partner Western Europe Award21.4.2026 10:52:00 EEST | Press release
Comwrap Reply, the Reply company specialised in cloud-native digital experience services, has received the Adobe CXO Emerging Partner Western Europe Award, one of the recognitions presented as part of the Adobe Customer Experience Orchestration Partner Awards, which honour companies that have made significant contributions to Adobe’s business and delivered a tangible impact on customer success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421234434/en/ The award is part of a long-standing collaboration with Adobe, recently reaffirmed by the renewal of Comwrap Reply’s Adobe Platinum Solution Partner status, and highlights the experience gained in developing digital experience solutions on Adobe Experience Cloud. The recognition confirms Comwrap Reply’s role in supporting organisations in the design and evolution of digital platforms based on Adobe Experience Cloud, capable of integrating content, data and customer journe
Comwrap Reply Recognized With the Adobe CXO Emerging Partner Western Europe Award21.4.2026 10:52:00 EEST | Press release
Comwrap Reply, the Reply company specialised in cloud-native digital experience services, has received the Adobe CXO Emerging Partner Western Europe Award, one of the recognitions presented as part of the Adobe Customer Experience Orchestration Partner Awards, which honour companies that have made significant contributions to Adobe’s business and delivered a tangible impact on customer success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421234434/en/ The award is part of a long-standing collaboration with Adobe, recently reaffirmed by the renewal of Comwrap Reply’s Adobe Platinum Solution Partner status, and highlights the experience gained in developing digital experience solutions on Adobe Experience Cloud. The recognition confirms Comwrap Reply’s role in supporting organisations in the design and evolution of digital platforms based on Adobe Experience Cloud, capable of integrating content, data and customer journe
Lenovo Brings Production-Scale AI to Hannover Messe 2026, Delivering Up to 85% Faster Lead Times for Manufacturers21.4.2026 10:00:00 EEST | Press release
Manufacturers are under increasing pressure to improve efficiency, resilience, and responsiveness in the face of ongoing supply chain volatility and rising operational complexity. In this environment, AI is no longer a future ambition but an operational necessity. With 94% planning to increase AI investment in 20261 and an expected $2.86 return for every dollar spent2, the priority has shifted from experimentation to execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421992136/en/ ThinkStation PGX and Lenovo ThinkEdge Solution 2 At Hannover Messe 2026, Lenovo in partnership with NVIDIA are demonstrating how manufacturers can close that gap by deploying AI solutions already proven at scale across its own global operations, delivering measurable improvements in lead time, cost, quality, and productivity. “Manufacturers don’t need more AI pilots. They need AI that runs at scale in production,” said Jonathan Wu, Chief
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom